Patent · US Active

Inhibiting (α-v)(β-6) integrin

US11739087B2 · kind B2 · utility

2Cited by

16References

9Claims

0Family size

Assignee

Morphic Therapeutic, Inc. · US

Inventors

Bryce A. Harrison · Framingham, US
James E. Dowling · Lexington, US
Matthew G. Bursavich · Tuckahoe, US
Dawn M. Troast · Bedford, US
Blaise S. Lippa · Newton, US
Bruce N. Rogers · Belmont, US
Kristopher N. Hahn · Medford, US
Cheng Zhong · Belmont, US
Qi Qiao · San Diego, US
Fu-Yang Lin · Sudbury, US
Brian Sosa · Cambridge, US
Aleksey I. Gerasyuto · Flemington, US
Andrea Bortolato · Cambridge, GB
Mats A. Svensson · New York, US
Eugene Richard Hickey · Danbury, US
Kyle D. Konze · New York, US
Tyler Day · New York, US
Byungchan Kim · West New York, US

Key dates

Filing date	Apr 23, 2021
Grant date	Aug 29, 2023
Priority date	—
Expiry date	Jun 22, 2041

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K9/0053
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed are small molecule inhibitors of αvβ6 integrin, and methods of using them to treat a number of diseases and conditions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.